Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab

Autor: Yan Wu, Chulang Yu, Feng Gao, Guili He, Nantao Hu, Mengjun Shu, Yanjie Su, Zhi Yang, Zhihua Zhou, Min Zeng, Lin Xu
Rok vydání: 2020
Předmět:
Small interfering RNA
Materials science
Receptor
ErbB-3
Cell Survival
medicine.medical_treatment
Down-Regulation
Bioengineering
Breast Neoplasms
02 engineering and technology
Gene delivery
010402 general chemistry
01 natural sciences
Targeted therapy
Trastuzumab
Cell Line
Tumor
Antineoplastic Combined Chemotherapy Protocols
Chlorocebus aethiops
medicine
Animals
Humans
General Materials Science
Electrical and Electronic Engineering
RNA
Small Interfering
skin and connective tissue diseases
Cell Proliferation
Cell growth
Mechanical Engineering
Cell Cycle
Drug Synergism
General Chemistry
Transfection
021001 nanoscience & nanotechnology
Carbon
0104 chemical sciences
body regions
Gene Expression Regulation
Neoplastic
Mechanics of Materials
Cell culture
Drug Resistance
Neoplasm
Cancer cell
COS Cells
Cancer research
Female
0210 nano-technology
medicine.drug
Zdroj: Nanotechnology. 31(33)
ISSN: 1361-6528
Popis: Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab resulted in enhanced antitumor activity, which overcomes the resistance to trastuzumab monotherapy. Herein, we have developed branched polyethylenimine-functionalized carbon dot (BP-CD) nanocarriers, which exhibited efficient green fluorescent protein gene delivery and expression. The positively charged BP-CDs allowed for effective nucleic acid binding and displayed a highly efficient small interfering RNA (siRNA)-mediated delivery targeting of cancer cells. The transfection of BP-CDs and HER3 siRNA complexes down-regulated HER3 protein expression and induced significant cell growth inhibition in BT-474 cells. BP-CDs/HER3 siRNA complexes induced cell death of BT-474 cells through G0/G1 cell cycle arrest and apoptosis. The combined treatment of BP-CDs/HER3 siRNA complexes and trastuzumab caused greater cell growth suppression in BT-474 cells when compared to either agent alone. The findings suggest that this dual-targeted therapy with the combination of BP-CDs/HER3 siRNA and trastuzumab represents a promising approach in breast cancer.
Databáze: OpenAIRE
Externí odkaz: